Bridging the gap between in vitro and in vivo models: a way forward to clinical translation of mitochondrial transplantation in acute disease states.

Autor: Bodenstein DF; Department of Pharmacology and Toxicology, University of Toronto, Medical Science Building, Room 4211, 1 King's College Circle, Toronto, ON, M5S 1A8, Canada.; Mitochondrial Innovation Initiative (MITO2i), Toronto, Canada., Siebiger G; Institute of Medical Science (IMS), University of Toronto, Toronto, Canada.; Latner Thoracic Research Laboratories, Toronto General Hospital, Toronto, Canada.; Mitochondrial Innovation Initiative (MITO2i), Toronto, Canada., Zhao Y; Institute of Biomedical Engineering, University of Toronto, Toronto, ON, M5S 3G9, Canada.; Mitochondrial Innovation Initiative (MITO2i), Toronto, Canada., Clasky AJ; Department of Chemical Engineering and Applied Chemistry, University of Toronto, Toronto, Canada.; Mitochondrial Innovation Initiative (MITO2i), Toronto, Canada., Mukkala AN; Institute of Medical Science (IMS), University of Toronto, Toronto, Canada.; Keenan Research Centre for Biomedical Science, Unity Health Toronto, Toronto, Canada.; Mitochondrial Innovation Initiative (MITO2i), Toronto, Canada., Beroncal EL; Department of Pharmacology and Toxicology, University of Toronto, Medical Science Building, Room 4211, 1 King's College Circle, Toronto, ON, M5S 1A8, Canada.; Mitochondrial Innovation Initiative (MITO2i), Toronto, Canada., Banh L; Institute of Biomedical Engineering, University of Toronto, Toronto, ON, M5S 3G9, Canada.; Osteoarthritis Research Program, Division of Orthopedic Surgery, Schroeder Arthritis Institute, University Health Network, Toronto, Canada.; Krembil Research Institute, University Health Network, Toronto, Canada., Aslostovar L; Centre for Commercialization of Regenerative Medicine, Toronto, Canada., Brijbassi S; Mitochondrial Innovation Initiative (MITO2i), Toronto, Canada., Hogan SE; Regenerative Medicine Department, United Therapeutics Corporation, Silver Spring, USA., McCully JD; Harvard Medical School, Boston, USA.; Department of Cardiac Surgery, Boston Children's Hospital, Boston, USA., Mehrabian M; Centre for Commercialization of Regenerative Medicine, Toronto, Canada., Petersen TH; Regenerative Medicine Department, United Therapeutics Corporation, Silver Spring, USA., Robinson LA; Program in Cell Biology, The Hospital for Sick Children Research Institute, Toronto, Canada., Walker M; Department of Neurological Surgery, University of Washington, Seattle, USA., Zachos C; Mitochondrial Innovation Initiative (MITO2i), Toronto, Canada., Viswanathan S; Institute of Biomedical Engineering, University of Toronto, Toronto, ON, M5S 3G9, Canada.; Osteoarthritis Research Program, Division of Orthopedic Surgery, Schroeder Arthritis Institute, University Health Network, Toronto, Canada.; Mitochondrial Innovation Initiative (MITO2i), Toronto, Canada., Gu FX; Institute of Biomedical Engineering, University of Toronto, Toronto, ON, M5S 3G9, Canada.; Department of Chemical Engineering and Applied Chemistry, University of Toronto, Toronto, Canada.; Mitochondrial Innovation Initiative (MITO2i), Toronto, Canada.; Acceleration Consortium, University of Toronto, Toronto, ON, Canada., Rotstein OD; Mitochondrial Innovation Initiative (MITO2i), Toronto, Canada.; Li Ka Shing Knowledge Institute, Unity Health Toronto, Toronto, Canada.; Department of Surgery, University of Toronto, Toronto, Canada., Cypel M; Latner Thoracic Research Laboratories, Toronto General Hospital, Toronto, Canada.; Mitochondrial Innovation Initiative (MITO2i), Toronto, Canada.; Toronto Lung Transplant Program, Division of Thoracic Surgery, Department of Surgery, University Health Network, University of Toronto, Toronto, ON, M5G 2C4, Canada., Radisic M; Institute of Biomedical Engineering, University of Toronto, Toronto, ON, M5S 3G9, Canada.; Department of Chemical Engineering and Applied Chemistry, University of Toronto, Toronto, Canada.; Mitochondrial Innovation Initiative (MITO2i), Toronto, Canada.; Acceleration Consortium, University of Toronto, Toronto, ON, Canada.; Toronto General Hospital Research Institute, University Health Network, Toronto, ON, M5G 2C4, Canada.; Terence Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, Toronto, ON, M5S 3E1, Canada., Andreazza AC; Department of Pharmacology and Toxicology, University of Toronto, Medical Science Building, Room 4211, 1 King's College Circle, Toronto, ON, M5S 1A8, Canada. ana.andreazza@utoronto.ca.; Mitochondrial Innovation Initiative (MITO2i), Toronto, Canada. ana.andreazza@utoronto.ca.; Department of Psychiatry, University of Toronto, Toronto, ON, Canada. ana.andreazza@utoronto.ca.
Jazyk: angličtina
Zdroj: Stem cell research & therapy [Stem Cell Res Ther] 2024 May 31; Vol. 15 (1), pp. 157. Date of Electronic Publication: 2024 May 31.
DOI: 10.1186/s13287-024-03771-8
Abstrakt: Mitochondrial transplantation and transfer are being explored as therapeutic options in acute and chronic diseases to restore cellular function in injured tissues. To limit potential immune responses and rejection of donor mitochondria, current clinical applications have focused on delivery of autologous mitochondria. We recently convened a Mitochondrial Transplant Convergent Working Group (CWG), to explore three key issues that limit clinical translation: (1) storage of mitochondria, (2) biomaterials to enhance mitochondrial uptake, and (3) dynamic models to mimic the complex recipient tissue environment. In this review, we present a summary of CWG conclusions related to these three issues and provide an overview of pre-clinical studies aimed at building a more robust toolkit for translational trials.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje